Literature DB >> 17825674

Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies.

Nazli Hossain1, Michael J Paidas.   

Abstract

Adverse pregnancy outcome (APO), includes fetal loss > or =20 weeks' gestation (fetal death), severe preeclampsia <36 weeks, or severe intrauterine growth restriction (severe IUGR) defined as birth weight < or =5th percentile or < or =10th percentile for gestational age. APO affects 8% of pregnant women (320,000 annually) and collectively contributes to the largest proportion of maternal/fetal mortality and morbidity. Women with prior APO in antecedent pregnancy are at high risk of an adverse maternal or fetal outcome in the subsequent pregnancy. Maternal serum markers and Doppler ultrasound can be used to predict adverse pregnancy outcome. There are no adequate, completed randomized trials for prophylactic measures; the roles of aspirin, calcium, and low molecular weight heparin need to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825674     DOI: 10.1053/j.semperi.2007.05.002

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  12 in total

1.  Maternal low molecular weight heparin versus sildenafil citrate for fetal growth restriction: a randomized, parallel groups, open-label clinical trial.

Authors:  R Rasheedy; G El Bishry; R Tarek
Journal:  J Perinatol       Date:  2019-11-06       Impact factor: 2.521

2.  Non-O blood group and outcomes of in vitro fertilization.

Authors:  M Di Nisio; A Ponzano; G M Tiboni; M D Guglielmi; A W S Rutjes; E Porreca
Journal:  J Assist Reprod Genet       Date:  2018-04-20       Impact factor: 3.412

3.  Sildenafil increases uterine blood flow in nonpregnant nulliparous women.

Authors:  Sarah A Hale; Cresta W Jones; George Osol; Adrienne Schonberg; Gary J Badger; Ira M Bernstein
Journal:  Reprod Sci       Date:  2010-04       Impact factor: 3.060

4.  Body composition and newborn birthweight in pregnancies of adolescent and mature women.

Authors:  María Elena Contreras Campos; Nora Rodríguez-Cervantes; Sandra Reza-López; Marina Ávila-Esparza; Dora Virginia Chávez-Corral; Margarita Levario-Carrillo
Journal:  Matern Child Nutr       Date:  2012-08-23       Impact factor: 3.092

5.  Estradiol Elicits Proapoptotic and Antiproliferative Effects in Human Trophoblast Cells.

Authors:  Shivali Patel; Brian Kilburn; Anthony Imudia; D Randall Armant; Debra F Skafar
Journal:  Biol Reprod       Date:  2015-08-05       Impact factor: 4.285

6.  Elevated first trimester soluble fibrin polymer is associated with adverse pregnancy outcome in thrombophilic patients.

Authors:  Michael J Paidas; De-Hui W Ku; Gabriele Urban; Nazli Hossain; Andrei Rebarber; Charles J Lockwood; Yale S Arkel
Journal:  Blood Coagul Fibrinolysis       Date:  2008-12       Impact factor: 1.276

7.  Parent Joint AB Blood Group Is Associated With Clinical Outcomes of in vitro Fertilization and Intracytoplasmic Sperm Injection Treatment in Chinese Women.

Authors:  Xiao Bao; Feifei Zhao; Hao Shi; Zhiqin Bu; Yuling Liang; Yingpu Sun
Journal:  Front Med (Lausanne)       Date:  2022-05-04

8.  The impact of close surveillance on pregnancy outcome among women with a prior history of antepartum complications attributed to thrombosis: a cohort study.

Authors:  Raed Salim; Tali Czarnowicki; Zohar Nachum; Eliezer Shalev
Journal:  Reprod Biol Endocrinol       Date:  2008-11-21       Impact factor: 5.211

9.  Altered Biomarkers in Trophoblast Cells Obtained Noninvasively Prior to Clinical Manifestation of Perinatal Disease.

Authors:  Jay M Bolnick; Hamid-Reza Kohan-Ghadr; Rani Fritz; Alan D Bolnick; Brian A Kilburn; Michael P Diamond; D Randall Armant; Sascha Drewlo
Journal:  Sci Rep       Date:  2016-09-23       Impact factor: 4.379

10.  Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP).

Authors:  Edurne Mazarico; Anna Peguero; Marta Camprubí; Carlota Rovira; Maria Dolores Gomez Roig; Daniel Oros; Patricia Ibáñez-Burillo; Jon Schoorlemmer; Narcís Masoller; Maria Dolors Tàssies; Francesc Figueras
Journal:  BMJ Open       Date:  2018-10-23       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.